291 filings
Page 2 of 15
POS AM
y154otx8h0yq
3 Jun 22
Prospectus update (post-effective amendment)
4:16pm
25
6njoteyhv oon
2 Jun 22
Voluntary exchange delisting
4:40pm
8-K
8ml nh9y25
1 Jun 22
Departure of Directors or Certain Officers
4:09pm
8-K
bym9c
24 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:10am
8-K
ebdb2dn
28 Apr 22
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
4:18pm
S-8
f6brqo7m
18 Mar 22
Registration of securities for employees
4:07pm
8-K
1jzjsorl
10 Mar 22
Genocea Provides Fourth Quarter 2021 Corporate Update
8:01am
8-K
3hmrkuz4l51487wbbf
7 Mar 22
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
4:19pm
8-K
w0km0jr64gopfx90apd
4 Jan 22
Genocea Biosciences Provides Corporate Update
7:03am
8-K
va79p9 0iwm0dto5lq
28 Oct 21
Genocea Provides Third Quarter 2021 Corporate Update
7:42am
8-K
n4ld7r
13 Sep 21
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
4:55pm
8-K
mty584
29 Jul 21
Genocea Provides Second Quarter 2021 Corporate Update
8:24am
8-K
wcegjn8c
13 Jul 21
Regulation FD Disclosure
8:46am
8-K
upnc2fkx 1dow
24 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
xxya4
4 Jun 21
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
4:04pm